Tag Archives: abbv

AbbVie Beats, But Stock Falls; Lilly Cuts Guidance

Two of the world’s biggest drugmakers issued a mixture of Q4 reports Friday in what continues to be a tough earnings season. AbbVie (ABBV) said profit excluding one-time items rose 8.5% over the year-earlier quarter to 89 cents, beating analysts’ consensus by 3 cents, according to Thomson Reuters. Sales climbed 5.1% to $5.37 billion, $11 million ahead of consensus. For the full year, profit increased 5.7% to $3.32 a share, with sales gaining 6.2%

Gilead, AbbVie Hep C Price Cuts Seen Hitting Sales

As the price war over the new hepatitis C drugs heats up, the 2015 consensus estimates for both may be too high, according to Deutsche Bank. In two separate notes Tuesday and Wednesday, analyst Robyn Karnauskas calculated the prospects for AbbVie’s (ABBV) Viekira Pak and Gilead Sciences’ (GILD) Harvoni and Sovaldi after the two companies announced a series of exclusive agreements with payers and pharmacy benefit managers. “ABBV has so far nailed

Gilead, AbbVie Hepatitis C Price Cuts Will Hit Sales

As the price war over the new hepatitis C drugs heats up, the 2015 consensus estimates for both may be too high, according to Deutsche Bank. In two separate notes Tuesday and Wednesday, analyst Robyn Karnauskas calculated the prospects for AbbVie’s (ABBV) Viekira Pak and Gilead Sciences’ (GILD) Harvoni and Sovaldi after the two companies announced a series of exclusive agreements with payers and pharmacy benefit managers. “ABBV has so far nailed